These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Deep immune profiling reveals targetable mechanisms of immune evasion in immune checkpoint inhibitor-refractory glioblastoma. Simonds EF; Lu ED; Badillo O; Karimi S; Liu EV; Tamaki W; Rancan C; Downey KM; Stultz J; Sinha M; McHenry LK; Nasholm NM; Chuntova P; Sundström A; Genoud V; Shahani SA; Wang LD; Brown CE; Walker PR; Swartling FJ; Fong L; Okada H; Weiss WA; Hellström M J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34083417 [TBL] [Abstract][Full Text] [Related]
7. Dendritic cell-mediated delivery of doxorubicin-polyglycerol-nanodiamond composites elicits enhanced anti-cancer immune response in glioblastoma. Li TF; Li K; Zhang Q; Wang C; Yue Y; Chen Z; Yuan SJ; Liu X; Wen Y; Han M; Komatsu N; Xu YH; Zhao L; Chen X Biomaterials; 2018 Oct; 181():35-52. PubMed ID: 30071380 [TBL] [Abstract][Full Text] [Related]
8. Poly(I:C) primes primary human glioblastoma cells for an immune response invigorated by PD-L1 blockade. De Waele J; Marcq E; Van Audenaerde JR; Van Loenhout J; Deben C; Zwaenepoel K; Van de Kelft E; Van der Planken D; Menovsky T; Van den Bergh JM; Willemen Y; Pauwels P; Berneman ZN; Lardon F; Peeters M; Wouters A; Smits EL Oncoimmunology; 2018; 7(3):e1407899. PubMed ID: 29399410 [TBL] [Abstract][Full Text] [Related]
9. Peritumoral administration of DRibbles-pulsed antigen-presenting cells enhances the antitumor efficacy of anti-GITR and anti-PD-1 antibodies via an antigen presenting independent mechanism. Patel JM; Cui Z; Wen ZF; Dinh CT; Hu HM J Immunother Cancer; 2019 Nov; 7(1):311. PubMed ID: 31747946 [TBL] [Abstract][Full Text] [Related]
10. Phenotypic profile of dendritic and T cells in the lymph node of Balb/C mice with breast cancer submitted to dendritic cells immunotherapy. da Cunha A; Antoniazi Michelin M; Cândido Murta EF Immunol Lett; 2016 Sep; 177():25-37. PubMed ID: 27423825 [TBL] [Abstract][Full Text] [Related]
11. Local Targeting of NAD Li M; Kirtane AR; Kiyokawa J; Nagashima H; Lopes A; Tirmizi ZA; Lee CK; Traverso G; Cahill DP; Wakimoto H Cancer Res; 2020 Nov; 80(22):5024-5034. PubMed ID: 32998997 [TBL] [Abstract][Full Text] [Related]
12. A TLR3-Specific Adjuvant Relieves Innate Resistance to PD-L1 Blockade without Cytokine Toxicity in Tumor Vaccine Immunotherapy. Takeda Y; Kataoka K; Yamagishi J; Ogawa S; Seya T; Matsumoto M Cell Rep; 2017 May; 19(9):1874-1887. PubMed ID: 28564605 [TBL] [Abstract][Full Text] [Related]
13. Sustained localized delivery of immunotherapy to lymph nodes reverses immunosuppression and increases long-term survival in murine glioblastoma. Choi J; Pant A; Medikonda R; Kim YH; Routkevitch D; Saleh L; Tong L; Chan HY; Nedrow J; Jackson C; Jackson C; Lim M Oncoimmunology; 2021; 10(1):1940673. PubMed ID: 34290904 [TBL] [Abstract][Full Text] [Related]
14. Combination immunotherapy strategies for glioblastoma. Chan HY; Choi J; Jackson C; Lim M J Neurooncol; 2021 Feb; 151(3):375-391. PubMed ID: 33611705 [TBL] [Abstract][Full Text] [Related]
15. Dendritic cells cross-talk with tumour antigen-specific CD8 Eiraku Y; Terunuma H; Yagi M; Deng X; Nicol AJ; Nieda M Clin Exp Immunol; 2018 Oct; 194(1):54-66. PubMed ID: 30009488 [TBL] [Abstract][Full Text] [Related]
16. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Zeng J; See AP; Phallen J; Jackson CM; Belcaid Z; Ruzevick J; Durham N; Meyer C; Harris TJ; Albesiano E; Pradilla G; Ford E; Wong J; Hammers HJ; Mathios D; Tyler B; Brem H; Tran PT; Pardoll D; Drake CG; Lim M Int J Radiat Oncol Biol Phys; 2013 Jun; 86(2):343-9. PubMed ID: 23462419 [TBL] [Abstract][Full Text] [Related]
17. Immunovirotherapy with measles virus strains in combination with anti-PD-1 antibody blockade enhances antitumor activity in glioblastoma treatment. Hardcastle J; Mills L; Malo CS; Jin F; Kurokawa C; Geekiyanage H; Schroeder M; Sarkaria J; Johnson AJ; Galanis E Neuro Oncol; 2017 Apr; 19(4):493-502. PubMed ID: 27663389 [TBL] [Abstract][Full Text] [Related]
18. Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model. Reardon DA; Gokhale PC; Klein SR; Ligon KL; Rodig SJ; Ramkissoon SH; Jones KL; Conway AS; Liao X; Zhou J; Wen PY; Van Den Abbeele AD; Hodi FS; Qin L; Kohl NE; Sharpe AH; Dranoff G; Freeman GJ Cancer Immunol Res; 2016 Feb; 4(2):124-35. PubMed ID: 26546453 [TBL] [Abstract][Full Text] [Related]
19. Predictors of Response to Autologous Dendritic Cell Therapy in Glioblastoma Multiforme. Jan CI; Tsai WC; Harn HJ; Shyu WC; Liu MC; Lu HM; Chiu SC; Cho DY Front Immunol; 2018; 9():727. PubMed ID: 29910795 [TBL] [Abstract][Full Text] [Related]
20. CCR2 inhibition reduces tumor myeloid cells and unmasks a checkpoint inhibitor effect to slow progression of resistant murine gliomas. Flores-Toro JA; Luo D; Gopinath A; Sarkisian MR; Campbell JJ; Charo IF; Singh R; Schall TJ; Datta M; Jain RK; Mitchell DA; Harrison JK Proc Natl Acad Sci U S A; 2020 Jan; 117(2):1129-1138. PubMed ID: 31879345 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]